Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $42.31 USD
Change Today -0.46 / -1.08%
Volume 434.5K
THOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

thoratec corp (THOR) Snapshot

Open
$42.82
Previous Close
$42.77
Day High
$43.29
Day Low
$42.25
52 Week High
04/16/15 - $44.74
52 Week Low
08/7/14 - $22.50
Market Cap
2.3B
Average Volume 10 Days
533.1K
EPS TTM
$0.86
Shares Outstanding
54.2M
EX-Date
--
P/E TM
49.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for THORATEC CORP (THOR)

thoratec corp (THOR) Related Businessweek News

No Related Businessweek News Found

thoratec corp (THOR) Details

Thoratec Corporation, together with its subsidiaries, develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients. The company’s primary product lines include ventricular assist devices, including HeartMate II, an implantable, electrically powered, continuous flow, left ventricular assist device (LVAD) consisting of a rotary blood pump designed to provide intermediate and long-term mechanical circulatory support (MCS); CentriMag an extracorporeal circulatory support device that provides hemodynamic stabilization in patients in need of cardiopulmonary support. It also offers PediMag and PediVAS extracorporeal full-flow acute surgical support platforms incorporating a polycarbonate pump, based on magnetically levitated bearingless motor technology, designed to provide acute surgical support to pediatric patients. In addition, it provides Thoratec Paracorporeal Ventricular Assist Device (PVAD) an external, pulsatile ventricular assist device (VAD), FDA-approved for bridge-to-transplantation (BTT) and post-cardiotomy myocardial recovery; and Thoratec Implantable Ventricular Assist Device (IVAD) an implantable, pulsatile, VAD, FDA-approved for BTT, including home discharge, and post-cardiotomy myocardial recovery and provides left, right or biventricular MCS The company markets its products through cardiovascular sales specialists and distributors in the United States and internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.

954 Employees
Last Reported Date: 02/19/15
Founded in 1976

thoratec corp (THOR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $201.9K
Chief Financial Officer and Vice President
Total Annual Compensation: $341.3K
President of North America
Total Annual Compensation: $233.1K
Senior Vice President and General Counsel
Total Annual Compensation: $355.8K
Senior Vice President of Technical Operations
Total Annual Compensation: $190.7K
Compensation as of Fiscal Year 2014.

thoratec corp (THOR) Key Developments

Thoratec Corporation Announces Encouraging Results from Heart Failure Study

Thoratec Corporation has announced encouraging results from the Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients, or ROADMAP, study which demonstrate benefit of HeartMate II LVAD support in ambulatory advanced heart failure patients. For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory NYHA Class IIIB/IV (INTERMACS profile 4-7) heart failure patients. Survival in the HeartMate II group was 80% at one year, compared with 64% for medically managed patients on an as-treated basis. At one year of follow-up, 39% of patients within the HeartMate II group met the primary endpoint of survival on the original therapy along with a 75 meter increase in six minute walk test distance, compared with 21% of patients on optimal medical management, representing a statistically significant difference (p=0.017). These benefits came despite the fact that the LVAD cohort was more severely ill, with 65% of HeartMate II patients designated as INTERMACS profile 4 at baseline, compared with just 34% in the medical management group. Moreover, 17 patients in the optimal medical management group received delayed LVAD implants during the first year as a result of worsening heart failure, and results from these patients will be fully analyzed at two-year follow-up. Overall functional improvement significantly favored HeartMate II support as measured by changes in six minute walk distance, health related quality of life, and NYHA classification. Within the LVAD group, 77% of patients at twelve months improved to NYHA Class I or II status compared with only 29% in NYHA Class II and no Class I patients in the optimal medical management group. Quality of life metrics favored HeartMate II despite the fact that adverse events in total were higher than with medical management. Adverse events were similar to rates observed in the Destination Therapy clinical trial, with bleeding the most frequent adverse event. Pump thrombus in this contemporary cohort was 1.1% at 90 days and 6.4% at one-year, with pump exchange for thrombus of 4.3% at one-year. Additionally, 30 day mortality within the LVAD group was only 1%, equivalent to optimal medical management.

Thoratec Corp. - Shareholder/Analyst Call

Thoratec Corp. - Shareholder/Analyst Call

Thoratec Receives Approval from FDA for Full Expansion of HeartMate III™ U.S. IDE Clinical Trial

Thoratec Corporation announced that it received final approval from the FDA to broaden enrollment of the HeartMate III U.S. clinical trial of up to 1,028 patients in up to 60 sites. This was based on the FDA's evaluation of safety data from the first ten HeartMate III implants performed in recent months during a limited enrollment phase at five sites. HeartMate III is a centrifugal-flow chronic left ventricular assist system, utilizing a fully magnetically levitated technology foundation, designed to lower adverse event rates while also enhancing the ease of surgical placement through a compact size. Additionally, Thoratec announced that it has named co-principal investigators for the HeartMate III U.S. clinical trial. They are Dr. Mandeep Mehra, Medical Director of the Brigham and Women's Health Heart and Vascular Center, Executive Director of the Center for Advanced Heart Disease, and Professor of Medicine at Harvard Medical School; Dr. Daniel Goldstein, Professor and Vice-Chair of the Department of Cardiothoracic Surgery and Surgical Director of the Mechanical Assistance Program at Montefiore Medical Center; Dr. Nir Uriel, Associate Professor of Medicine and Medical Director of the Heart Failure, Heart Transplant and Mechanical Assist Device Programs of the Division of Cardiology at the University of Chicago; and Dr. Joseph Cleveland Jr., Professor of Surgery and Surgical Director of Cardiac Transplantation and Mechanical Circulatory Support at the University of Colorado Anschutz Medical Center.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THOR:US $42.31 USD -0.46

THOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $62.89 USD -0.30
ICU Medical Inc $88.27 USD +0.195
Masimo Corp $34.83 USD -0.07
Merit Medical Systems Inc $20.58 USD +1.34
NuVasive Inc $43.99 USD +0.23
View Industry Companies
 

Industry Analysis

THOR

Industry Average

Valuation THOR Industry Range
Price/Earnings 48.1x
Price/Sales 4.9x
Price/Book 3.7x
Price/Cash Flow 46.0x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THORATEC CORP, please visit www.thoratec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.